were crossed over from their initial assign ed therapy due to drug toxicity. In the second study of 70 patients, t h e survival in TMP-SMZ-treated patients was high er (86 versus 61 o/o) and this difference was statistically s ignificant (P=0 .03) (6). Furthermore, there were n o cross-overs during this study. It appears, therefore, that TMP-SMZ may be more effective than pentamidine in s u bj ects able to remain on therapy.
Medina et al (7) conducted a prospective randomized trial comparing TMP-SMZ with a combination of TMP and dapsone in AIDS-associated PCP. They fo u nd equivalent efficacy of the two therapies but lesser toxicity in the TMP and Dapsone group, of which 3 0% ex'Perienced treatment limiting adverse effects, compared with 57o/o of patients treated with TMP-SMZ (P<0.025).
Two studies have compared the rela tive efficacy of intravenous pentamidine with th at of aerosolized pentamidine (8, 9) . Both studies demonstrated clearly that aerosolized pentamidine was less effective than intravenous pentamidine .
The role of adjunctive corticosteroids has also been studied in AIDS-associated PCP. Of five randomized con-trolled mals, three found a survival a dvantage for steroids including the two la rgest studies (10) . A fourth study found improved oxygenation and long term exercise tolerance in the steroid-treated group (11) . Only one of the five studies found no benefit from corticosteroids (12) . An expert panel has recently iss u ed a consens us statement recommending the use of a djunctive corticosteroids in AIDS-associated PCP when the initial room air P02 is below 70 mmHg ( 1 0). Unanswered questions: The major unanswered questions in PCP treatment relate to the relative efficacy of tl1erapies other than TMP-SMZ, TMP-dapsone and pentamidine. Specifically, the relative efficacy of clindamycin plus primaquine (13) . trimetrexate (14) , ellornithine (alpha-DFMO) (15) . and newer agents such as piritrexirn (16) . 9 -deazainosine (17) and 566C80 (18) .
A mal comparing clindamycin and primaquine to TMP-SMZ has been proposed by Dr Emil Toma through the Canadian HIV Clinical Trials Network and it is hopeful that this trial will get und erway in the near future. Trials with trtmetrexate and 566C80 are c u rrently ongoing in the United States through the AIDS Clinical Trial Group (ACTG). PCP prophylaxis -Answered questions: The efficacy of TMP-SMZ in the primary prophylaxis of PCP in HIV-infected individuals has been examined in a placebo-controlled mal in patients with Kaposi's sarcoma (19) . This study showed a potent effect of TMP-SMZ. The dose used was relatively high (one double strength tablet bid) and was associated with s ignificant toxicity. A recent uncontrolled study using one double strength tablet three days a week was 100% effective (20) indicating that lower doses of TMP-SMZ are also effective for PCP prophylaxis.
Aerosolized pentamidine h as also been shown to be effective in PCP prophylaxis in a placebo-controlled mal (unpublished data) when given by ultrasonic nebulizer. Aerosolized pentamidine given by j et nebulizer is also effective, as demonstrated in a comparison of three different doses where the two high er dosing regimens were clearly superior to the lowest dose used. which h as been considered by some to be a pseudoplacebo (21) .
Controlled trials of other potential drugs for PCP prophylaxis have not been published. but uncontrolled favorable results have been reported u s ing dapsone alone (22) . fansidar (23) and clindamycin plus primaquine (24). Unanswered questions: There is. as yet, no published study comparing the relative efficacy of the two most commonly used prophylactic treatments. namely TMP-SMZ and aerosolized pentamidine. However, such a trial , in secondary prophylaxis only. has been completed by the ACTG (protocol 021) . There also has been no comparison of the two m ajor devices for nebulizing aerosolized pentamidine. namely the Fisoneb ultrasonic nebulizer and the Respirgard II j et nebulizer (several other nebulizers exist). Furthermore. tl1e optimal neb-
Workshop-Opportunistic in fection in HIV ulizer , dose and body positioning for delivery of aerosolized pentamidine remain to be established (25) .
MYC OBACTERIUM AV/UM C OMPLEX INFECTION
Mycobacterium avium complex (MAC) infection is tl1e AIDS-defining event in fewer than 5% of cases (Federal Centre for AIDS data). However , MAC infection is diagnosed during life in 15 to 30% of AIDS patients and is found at a utopsy in up to 53% of cases (26) (27) (28) . While MAC infection is clearly a common late complication in AIDS, its contribution to mortality is questionable (29) . Nevertl1 eless. MAC infection can be an important cause of morbidity, causing fever. weight loss, diarrhea and , less frequently. focal disease in the biliary tract, lung and central nervous system (28) . MAC isolates are characteristically resistant in vitro to most antimycobacterial agents (26, 28) . recognizing t11at there are no clearly accepted standards for s usceptibility testing for nontuberculous mycobacteria. Answered questions: There are esse nti a lly no answered questions in this area. Unanswered questions: There is considera ble debate as to the merits of therapy for MAC infection du e to the following factors .
• The contribution of MAC to AIDS mortality is minimal.
• MAC isolates are multiresistant in vitro.
• In a numb er of patients, MAC infection is diagnosed at s u ch an advanced stage of AIDS that treatment may be inappropriate.
• The addition of three or four drugs to patients who generally a re already taking antiretroviral, anti-PCP and anticandidal t11erapy is problematic.
• The results of many of the early reports of treatment h ave been unfavorable. No controlled clinical mals in the treatment of MAC infection have ever been published. although a pilot study of clarithromycin monotherapy h as been reported in abstract form (30) . Th e initial reports of the resul ts of treating MAC infection in AIDS patients were unfavorable (31 -33); however, three more recent reports of combination drug therapy have been very encouraging (34) (35) (36) . For this reason. the pendulum appears to be swinging towards treating most symptomatic patients.
In JanuaJ.y 199 1. the Canadian HIV Trials Network approved a multicentre trial comparing tv.ro different regimens of combination therapy for MAC bacteremia. It was anticipated that the t.Iial would start in the summer of 1991.
In the United States, a t.Iial is proposed to compare the combination of rifabutin. etl1ambu tol and clofazimine to ethamb utol and clofazimine without rifabutin. Furthermore, it is a nticipated that trials using clarithromycin will commence witl1in the next year. based on tl1e en couraging pilot study from France noted above (30) .
Finally. there is presently an ongoing multicentre (37) . Furthermore. isolation of CMV from a variety of body sites in the absence of clear disea s e occurs commonly. particula rly in association with marked CD4 lymphopenia. Although CMV has been isolated from n early every organ in AIDS patients. definite evidence of disease occurs most commonly in the retina and bowel (37.38) . CMV retinitis occurs in 5 to 10o/o of AIDS patients and CMV enteritis is about half as prevalent (37 ,38) . It is unusual for both retinitis and enteritis to occur in the same individual (3 7 ,38). Answered questions: In the case of retinitis , intravenous ganciclovir has been approved for use in both the United Sta tes and Canada on the basis of open trials demonstrating efficacy (39) . Placebo-controlled trials have not been conducted because of an impression tha t disease invariably progresses in the absence of therapy. While a pproximately 85o/o of patients with CMV retinitis have a favorable response to ganciclovir. it is clear, that the majority of individuals will relapse after ganciclovir therapy necessitating maintenance therapy (37 ,38,40) ; however. even with maintenance therapy, deterioration occurs in atleast 50% of patients (38, 40) . Foscamet has also been shown to be effective for CMV retinitis in uncontrolled trials (41.42) . Unanswered questions: The obvious unanswered question is the comparison of the relative efficacy and toxicity of ganciclovir and foscarnet. Such a study is underway in the United States. The same trial was a pproved by the Canadian HIV Trials Network, but insufficient funding was available. A similar study in only 40 patients was condu cted in England and found similar response rates to th e two drugs (43) .
The addition of immunoglobulin (either polyclonal or CMV hyperimmune) to ganciclovir has improved the response of CMV pneumonia in bone marrow transplant recipients (44, 45) . The role of additional immunoglobulin therapy in CMV retinitis is unclear. but a pilot study suggested a lack of efficacy (46) . lntravitreal ganciclovir therapy has been successful (47.48). but generally has been reserved for patients who experienced excessive myelotoxicity with systemic ganciclovir. The relative efficacy of the intravitreal versus the intravenous route h as not been compared.
There are presently no published controlled trials of effective therapy for HIV-associated CMV enteritis, although there are anecdotal reports of favorable responses with ganciclovir (37 .38). In bone marrow transplant recipients, ganciclovir was no more effective tl1an placebo in reUeving symptoms of proven CMV enteritis , 84 despite a definite antiviral effect (49) . A placebo-controlled trial of ganciclovir for CMV colitis in 62 AIDS patients h as been presented in abstract form (50) . There was a m arked antiviral effect and a modest but not statistically significant clinical ben efit favouring ganciclovir.
CEREBRAL TOXOPLASMOSIS
Cerebral toxoplasmosis occurs in approximately 10o/o of AIDS patients (51) . Nearly all cases occur in patients seropositive for Toxoplasma gondii of whom approximately 30o/o will develop toxoplasmosis (51 ,52). Answered questions: It is clear that most AIDS patients with cerebral toxoplasmosis respond favorably to pyrimethamine and sulphadiazine therapy (51 -55). However, most patients successfully treated will relapse if tl1erapy is stopped altogether (53-55) ; therefore. maintenance therapy with reduced dose pyrimethamine and sulphadiazine is the standard treatment (51 ,53,56) .
Clindan1ycin with or without pyrimethan1ine is also effective in tl1e treatment of cerebral toxoplasmosis (57 -59) . The relative efficacy ofsulphadiazine plus pyrimetha.Dline versus clindamycin plus pyrimetl1amine for cerebral toxoplasmosis was evaluated by the California Collaborative Treatment Group (60) . Th e two regimens did not appear to differ in efficacy, although the sample size precludes a definitive statement of equivalence. Unanswered questions: A major unanswered question relates to tl1e role of prophylaxis in toxoplasma seropositive patients. It has been argu ed that prophylaxis is lli\:ely to be effective (61) . and should be evaluated (61. 62) . At this point, such a trial has not been published.
A potential problem for any study in cerebral toxoplasmosis will be whetl1er brain biopsy is required for diagnosis. since many clinicians do not routinely recommend confirming the diagnosis by brain biopsy (63) . This issue must be clearly addressed in any such bial.
CRYPTOCOCCOSIS
Cryptococcosis is reported in 5 to 13o/o of AIDS cases (64), with a lower incidence likely if oral azole therapy is initiated early to treat mucosal candidiasis. Therapy-Answered questions: Two major trials have compared the efficacy of amphotericin B witl1 that of fluconazole (65 ,66) . Larsen et al (65) compared tl1e combination of amphotericin B at a dosage of 0.7 mg/kg/ day, and flucytosine 150 mg/kg/ daywitl1 fluconazole 400 mg/ day and found that six of six amphotericin-treated patients had sterile cerebrospinal fluid at week 10, compared with five of 14 treated \villi fluconazole , a difference which was highly significant. As well. sterilization of the cerebrospinal fluid occurred significantly more rapidly with amphotericin B.
In contrast, the presently unpublished study conducted jointly by the Mycosis Study Group of the National Institute of Allergic and Infectious Diseases and tl1e ACTG showed comparable efficacy of the two u·eat-ments.
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Secondary prophylaxis: Fluconazole at a dose of 200 mg/ day reportedly is more effective than either placebo or amphotericin B given intravenously at a dosage of l mg/ kg once a week in the secondary prophylaxis of cryptococcal infection in AJDS patients (67, 68) .
Treatment-Unanswered questions:
The relative efficacy of amphotericin B versus triazoles is not entirely resolved, particularly as higher doses of triazoles than those used in previous trials may be tolerated. Furthermore, even if amphotericin B is the initial agent used , it may be possible to switch to triazoles at an earlier point than 10 weeks, perhaps dictated by a specified period after initial sterilization.
Flucytosine's role in the treatment of cryptococcosis remains controversial. In a frequently cited study conducted in the pre-AJDS era, the combination of amphotericin B plus flucytosine was more effective than amphotericin B alone (69) . This study has been criticized, however, because of the low dosage of amphotericin B chosen in both arms, and because the efficacy of the amphotericin B monotherapy arm was lower than historic controls (70) . A similar trial has not been conducted in AIDS patients. However, uncontrolled data from San Francisco do not suggest that combination therapy is more effective than amphotericin B monotherapy (71) . Also, the myelosuppressive properties of !1ucytosine make it difficult to use in AJDS patients .
The role ofliposome-encapsulated amphotericin Bin human cryptococcosis has not been evaluated, but such therapy is effective in murine cryptococcosis (72) . Prophylaxis: Whereas triazole antifungals such as itraconazole and saperconazole may prove to be as effective as fluconazole for secondary prophylaxis of cryptococcosis, is extremely doubtful that they will prove to be more effective.
PROPOSED CLINICAL TRIALS
On the basis of the above review. and extensive discussions in the workshop, the working group proposed two clinical trials.
ADDENDUM: Dr Shafran wishes to stress that AJDS is a rapidly changing field and that the manuscript was written in April 1991; thus , significant changes h ave occurred in this area s ince that Urne. Trial 1: 'A prospective randomized comparative trial of TMP plus dapsone versus aerosolized pentamidine for t11e prevention of PCP and toxoplasmosis .' The purpose of this trial is to answer two questions. First, to determine the relative efficacy of aerosolized pentamidine versus an orally absorbed systemic tl1erapy for PCP prevention . TMP plus dapsone was chosen over TMP-SMZ because TMP plus dapsone was shown to be better tolerated in a PCP treatment study (7) . and it was felt that it was less likely that such a trial was taking place elsewhere.
The second is to determine whether there is a role for prophylactic t11erapy for toxoplasmosis in HIV-infected individuals who are toxoplasma-seropositive. Altl1ough pyrimethamine plus sulphadiazine is the best studied treatment for toxoplasmosis, TMP plus dapsone was selected for the following reasons: this selection would facilitate answering two important clinical questions with one study design; and this combination is known to be effective in vitro and in animal models of toxoplasmosis (73.74) .
Therefore, in order to conduct this study properly, it was acknowledged t11at toxoplasma serology would be done in a single reference laboratory and that patients would be sb·atified according to their toxoplasma serological status. Patients were then to be randomly allocated 1:1 to aerosolized pentamidine versus TMP plus dapsone. Trial2: The working group felt frustrated by the clinical problem of CMV enteritis. Clinicians reported a perceived pressure to administer ganciclovir therapy in order to feel that something is being done. despite a lack of efficacy data. A consensus regarding the study design was not finalized. It was acknowledged that a placebocontrolled trial is indeed ethical, but might be imposs ible to carry out. Alternative trials included a comparison of ganciclovir with foscarnet, or a comparison of ganciclovir alone with ganciclovir plus eitl1er CMV immune globulin or polyclonal intravenous immunoglobuin. 
